drug maker mallinckrodt beating estimates. also beating forecasts on strength of double digit sales. that stock though right now down by just about a half a percent. given an upbeat earnings forecast. that does come ahead of scheduled meeting with analysts. it expects to earn 9.30 to 9.60 a share. up 3.2% right now. thor industries reporting a buck 39. well above estimates of 123 towable trailers were strong. >>> all right. we're just seconds away from a revision to third quarter gdp. what was it before? >> 2.9%. >> futures right now are indicated up 34. rick santelli standing by at the cme. the numbers, please. >> our second time around the block on third quarter gdp. an extra 0.3%. so 3.2% versus what joe just reiterated 2.9% was our first look. let's go through the internals. consumption important number. but we gained a bit. 2.8% versus 2.1%. if we look at the pricing index, 1.4% versus our last look at 1.5%. 1.7% on personal consumption expenditures. and that is unchanged from our last look. if we look at corporate profit

mallinckrodt. the xlv, which is the sector eftc for healthcare is off. losers, of individual lot of earnings story. found by 8%, volume was more than one and a quarter month dailyree average. but the outlook was very discouraging. facebook falling the most in nine months. start torowth will slow meaningfully. because of spending on data talent.s as well as the company cut its 2015 sale and shipment forecast. >> let's look at government bonds start -- basically nothing on here. tomorrow is jobs day. in the meantime, they'll be the next biggest econ. nothing happening. little more interesting in the front. let's check out u.k. in the morning after that boe interpreted was being slightly more hawkish. of jump upttle bit in yield. overall, the bonds were not center of the action today. was big focal point because that extension of that streak. let's look at currencies here. been on a losing streak. just five days ago, at an eight high. bloomberg dollar indexer, it's now on longest slide. today's big rumor was the british pound. double boost. who we were talk

moving to other areas of pressure we've been seeing today, this week mallinckrodt is coming under pressureas citron put out a new report challenging a drug, the price of that drug, saying that the medicare exposure of that drug is higher than investors were led to believe. analysts are defending this one, saying it's still a buy, but pressure is continuing formal inkrot. another specialty pharmaceutical company, mylan, the focus of a hearing by chuck grassley on november 30th over the misclassification of the epipen to medicaid. that hearing is happening november 30th. and in news coming out this week, the department of justice saying it hasn't agreed to any settlement around that. mile mylan saying it's working on finalizing it. >> thanks, meg terrell. >> there's no reason to buy the stock right now. there have been a couple of trading opportunities which we haven't been on the back of, granted. the stock has been straight line lower for the last year. mylan labs to me is the most interesting, because of valuation. they do have a business outside the epipen. with that said, if you're tryi